# Tailored Sonidegib Schedule After Complete Response in BCC

> **NCT04806646** · PHASE2 · UNKNOWN · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 21 (estimated)

## Conditions studied

- Locally Advanced Basal Cell Carcinoma

## Interventions

- **DRUG:** Sonidegib

## Key facts

- **NCT ID:** NCT04806646
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-12
- **Primary completion:** 2024-01-12
- **Final completion:** 2026-01-12
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2022-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04806646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04806646, "Tailored Sonidegib Schedule After Complete Response in BCC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04806646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*